Key facts
- It has raised $5.9M; the latest was Seed Round ($5.2M) in Jan 2025.
- Notable investors include Enterprise Ireland, European Innovation Council, European Investment Bank, 28DIGITAL, Horizon Europe — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for BioSimulytics
- ·The full record, as it builds
Funding rounds
No funding rounds for BioSimulytics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About BioSimulytics
Developer of an AI-enhanced predictive platform designed to assist pharmaceuticals with the development of drugs. The company's platform uses a combination of molecular chemistry, quantum physics, and artificial intelligence computing for crystal-structure prediction, enabling researchers to predict the stable polymorph, bringing speed, certainty, and product data quality.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2019
- Employees
- 8
- Website
- biosimulytics.com/
- Ownership
- Privately Held (backing)
BioSimulytics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioSimulytics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioSimulytics in its N-PORT filings yet. We sweep new filings monthly.